Holen Sie sich die Stockscreener-App
284.57
0.83%
-2.38
Vorhandelsmarkt:
289.88
5.31
+1.87%
Schlusskurs vom Vortag:
$286.95
Offen:
$291.12
24-Stunden-Volumen:
414.55K
Relative Volume:
1.45
Marktkapitalisierung:
$8.39B
Einnahmen:
$389.13M
Nettoeinkommen (Verlust:
$204.83M
KGV:
41.58
EPS:
6.8443
Netto-Cashflow:
$188.91M
1W Leistung:
+5.68%
1M Leistung:
+9.05%
6M Leistung:
+42.37%
1J Leistung:
+75.35%
1-Tages-Spanne:
$283.50
$303.00
1-Wochen-Bereich:
$251.97
$303.00
52-Wochen-Spanne:
$122.80
$303.00
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
284.57 | 8.39B | 389.13M | 204.83M | 188.91M | 6.8443 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus - sharewise.com
Krystal Biotech Q1 2026 Earnings Call Transcript - Sahm
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results - Benzinga
Krystal Biotech Q1 2026 earnings preview - MSN
Krystal Biotech stock hits all-time high at 301.99 USD - Investing.com
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2026 Earnings Call Transcript - Insider Monkey
A Look At Krystal Biotech (KRYS) Valuation After Recent Share Price Momentum - Yahoo Finance
Krystal Biotech Earnings Call Highlights Profitable Growth - TipRanks
Krystal Biotech Reports Strong Q1 2026 Earnings with VYJUVEK Gro - GuruFocus
Krystal Biotech jumps as Q1 results show strong VYJUVEK growth and upbeat pipeline/regulatory updates - Quiver Quantitative
Krystal Biotech Jumps 5.3% Amid Sector-Wide Rally - AlphaStreet
Why Is Krystal Biotech (KRYS) Jumping 5.2%? - AlphaStreet
Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end - MSN
Krystal Biotech Releases Q1 2026 Financial Results - AlphaStreet
Krystal Biotech, Inc. Reports Strong Q1 2026 Financial Results with $116 Million Revenue and Significant Net Income Growth - Minichart
Krystal (KRYS) Q1 2026 Earnings Transcript - The Globe and Mail
Krystal Biotech, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Krystal Biotech : First Quarter 2026 Earnings Call - marketscreener.com
KRYS: Q1 2026 delivered robust revenue and EPS growth, with expanding global VYJUVEK sales - TradingView
BofA cuts Krystal Biotech stock price target on revenue mix shift By Investing.com - Investing.com Australia
Krystal Biotech Reports Strong Q1 2026 Results: $116.4M VYJUVEK Revenue, Pipeline Advancements, and $1B Cash Reserves - Minichart
Krystal (KRYS) Q1 2025 Earnings Transcript - The Globe and Mail
Krystal Biotech, Inc. (KRYS) tops Q1 earnings and revenue estimates - MSN
BofA cuts Krystal Biotech stock price target on revenue mix shift - Investing.com UK
KRYS: Q1 revenue rose 32% to $116.4M, with robust margins and major clinical milestones ahead - TradingView
Krystal Biotech (KRYS) Projects FY26 R&D and SG&A Expenses of $1 - GuruFocus
Krystal Biotech Q1 Earnings Call Highlights - Yahoo Finance
Krystal Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Transcript : Krystal Biotech, Inc., Q1 2026 Earnings Call, May 04, 2026 - marketscreener.com
KRYS: Q1 revenue grew 32% year-over-year to $116.4M, with robust VYJUVEK sales and 95% gross margin - TradingView
Earnings call transcript: Krystal Biotech Q1 2026 beats earnings expectations By Investing.com - Investing.com Canada
Krystal Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Krystal Biotech (KRYS) Reports Strong Q1 Revenue, CEO Highlights Growth Momentum - GuruFocus
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
KRYSTAL BIOTECH ($KRYS) Releases Q1 2026 Earnings - Quiver Quantitative
Krystal Biotech stock rises over 6% on earnings beat and strong revenue By Investing.com - Investing.com South Africa
Krystal Biotech stock rises over 6% on earnings beat and strong revenue - Investing.com
Krystal Biotech reports $116.4M in sales as key eye study fills - Stock Titan
Earnings Flash (KRYS) Krystal Biotech Posts Q1 EPS $1.83, vs. FactSet Est of $1.44 - marketscreener.com
Krystal Biotech (NASDAQ: KRYS) spouses report 11.5% stake - Stock Titan
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q1 Revenue $116.4M, vs. FactSet Est of $112.1M - marketscreener.com
Krystal Biotech (KRYS) grows VYJUVEK sales 32% and advances late-stage gene therapy pipeline - Stock Titan
Strong VYJUVEK sales lift Krystal Biotech (NASDAQ: KRYS) Q1 profit - Stock Titan
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results - marketscreener.com
BRIEF-Krystal Biotech Q1 Net Income USD 55.932 Million - TradingView
What Krystal Biotech (KRYS)'s RMAT Win for KB707 in Lung Cancer Means For Shareholders - Sahm
Krystal Biotech (KRYS) Valuation Check After Strong One Year Shareholder Returns - Sahm
Trading the Move, Not the Narrative: (KRYS) Edition - Stock Traders Daily
How The Krystal Biotech (KRYS) Narrative Is Shifting With Vyjuvek And Late Stage Pipeline - Yahoo Finance
Krystal Biotech (KRYS) Q1 2026 Preview: EPS Est. $1.42, Reports May 4 - AlphaStreet
All eyes on Krystal Biotech earnings amid pipeline expansion - Investing.com UK
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):